Free Trial
NASDAQ:TELA

TELA Bio (TELA) Stock Price, News & Analysis

TELA Bio logo
$1.56 -0.05 (-3.11%)
As of 02:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About TELA Bio Stock (NASDAQ:TELA)

Advanced

Key Stats

Today's Range
$1.52
$1.66
50-Day Range
$1.47
$2.13
52-Week Range
$0.86
$3.26
Volume
177,067 shs
Average Volume
166,130 shs
Market Capitalization
$61.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
Consensus Rating
Moderate Buy

Company Overview

TELA Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

TELA MarketRank™: 

TELA Bio scored higher than 40% of companies evaluated by MarketBeat, and ranked 690th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    TELA Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Upside Potential

    TELA Bio has a consensus price target of $4.50, representing about 184.8% upside from its current price of $1.58.

  • Amount of Analyst Coverage

    TELA Bio has received no research coverage in the past 90 days.

  • Read more about TELA Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for TELA Bio are expected to grow in the coming year, from ($1.37) to ($0.66) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of TELA Bio is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of TELA Bio is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    TELA Bio has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about TELA Bio's valuation and earnings.
  • Percentage of Shares Shorted

    1.12% of the float of TELA Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    TELA Bio has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in TELA Bio has recently decreased by 7.99%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    TELA Bio does not currently pay a dividend.

  • Dividend Growth

    TELA Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.12% of the float of TELA Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    TELA Bio has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in TELA Bio has recently decreased by 7.99%, indicating that investor sentiment is improving significantly.
  • MarketBeat Follows

    2 people have added TELA Bio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, TELA Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.70% of the stock of TELA Bio is held by insiders.

  • Percentage Held by Institutions

    94.35% of the stock of TELA Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about TELA Bio's insider trading history.
Receive TELA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TELA Bio and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TELA Stock News Headlines

TELA Bio’s Earnings Call Highlights Robust Growth
Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
TELA Bio, Inc. (TELA) Q2 2025 Earnings Call Transcript
TELA Bio Reports Second Quarter 2025 Financial Results
See More Headlines

TELA Stock Analysis - Frequently Asked Questions

TELA Bio's stock was trading at $3.02 at the beginning of 2025. Since then, TELA shares have decreased by 47.7% and is now trading at $1.58.

TELA Bio, Inc. (NASDAQ:TELA) announced its quarterly earnings results on Monday, August, 11th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by $0.04. The firm earned $20.20 million during the quarter, compared to analysts' expectations of $20.67 million. TELA Bio had a negative net margin of 54.12% and a negative trailing twelve-month return on equity of 329.48%.
Read the conference call transcript
.

TELA Bio (TELA) raised $60 million in an initial public offering on Friday, November 8th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

TELA Bio's top institutional shareholders include Stonepine Capital Management LLC (5.27%), Geode Capital Management LLC (0.85%), JPMorgan Chase & Co. (0.15%) and Destiny Wealth Partners LLC (0.13%). Insiders that own company stock include Orbimed Advisors Llc, Opaleye Management Inc, Antony Koblish, Roberto Cuca, Paul Talmo and Gregory A Firestone.
View institutional ownership trends
.

Shares of TELA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that TELA Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX).

Company Calendar

Last Earnings
8/11/2025
Today
9/23/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:TELA
CIK
1561921
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

High Price Target
$7.00
Low Price Target
$2.00
Potential Upside/Downside
+184.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.84 million
Net Margins
-54.12%
Pretax Margin
-54.20%
Return on Equity
-329.48%
Return on Assets
-57.34%

Debt

Debt-to-Equity Ratio
4.14
Current Ratio
3.19
Quick Ratio
2.59

Sales & Book Value

Annual Sales
$69.30 million
Price / Sales
0.90
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.72 per share
Price / Book
2.19

Miscellaneous

Outstanding Shares
39,620,000
Free Float
37,754,000
Market Cap
$62.60 million
Optionable
Optionable
Beta
0.84

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:TELA) was last updated on 9/23/2025 by MarketBeat.com Staff
From Our Partners